CD44 as a stem cell marker in head and neck squamous cell carcinoma

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 321-326

  Faber, Anne ^a   Barth, Christine ^a   Hörmann, Karl ^a   Kassner, Stefan ^a   Schultz, Johannes David ^a   Sommer, Ulrich ^a   Stern Straeter, Jens ^a   Thorn, Carsten ^a   Goessler, Ulrich Reinhart ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer stem cells; CD44; Head and neck squamous cell carcinoma

Indexed keywords

CELL MARKER; HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ANTIGENS, CD44; CARCINOMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958200242     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1322     Document Type: Article

References (34)

1. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
2. Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007. (Pubitemid 46154721)
3. Zhang P, Zuo H, Ozaki T, Nakagomi N and Kakudo K: Cancer stem cell hypothesis in thyroid cancer. Pathol Int 56: 485-489, 2006. (Pubitemid 44258848)
4. Franzmann EJ, Reategui EP, Pedroso F, et al: Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16: 1348-1355, 2007. (Pubitemid 47076863)
5. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M and Kaibara N: Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83: 1094-1101, 1998. (Pubitemid 28419061)
6. Ponta H, Wainwright D and Herrlich P: The CD44 protein family. Int J Biochem Cell Biol 30: 299-305, 1998.
7. Screaton GR, Bell MV, Bell JI and Jackson DG: The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268: 12235-12238, 1993. (Pubitemid 23182367)
8. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992. (Pubitemid 23004805)
9. Picker LJ, Nakache M and Butcher EC: Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 109: 927-937, 1989. (Pubitemid 19197049)
10. Stamenkovic I, Amiot M, Pesando JM and Seed B: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56: 1057-1062, 1989. (Pubitemid 19091017)
11. Günthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991. (Pubitemid 121001209)
12. Hofmann M, Rudy W, Zoller M, et al: CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51: 5292-5297, 1991.
13. Thenappan A, Li Y, Shetty K, Johnson L, Reddy EP and Mishra L: New Therapeutics Targeting Colon Cancer Stem Cells. Curr Colorectal Cancer Rep 5: 209, 2009.
14. Zlobec I, Gunthert U, Tornillo L, et al: Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 55: 564-575, 2009.
15. Park SY, Lee HE, Li H, Shipitsin M, Gelman R and Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16: 876-887, 2010.
16. Okayama H, Kumamoto K, Saitou K, et al: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 22: 745-755, 2009.
17. Pries R, Wittkopf N, Hasselbacher K and Wollenberg B: Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines. HNO 56: 461-466, 2008 (In German).
18. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE and Puri RK: Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 1: 27, 2009.
19. Herold-Mende C, Seiter S, Born AI, et al: Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol 179: 66-73, 1996. (Pubitemid 26182867)
20. Mack B and Gires O: CD44s and CD44v6 expression in head and neck epithelia. PLoS One 3: e3360, 2008.
21. Van Hal NL, Van Dongen GA, Ten Brink CB, et al: Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 5: 3534-3541, 1999.
22. Halfon S, Abramov N, Grinblat B and Ginis I: Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 20: 53-66, 2011.
23. van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB and Brakenhoff RH: Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int J Cancer 82: 837-845, 1999. (Pubitemid 29384335)
24. Schirrmacher V: Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 43: 1-73, 1985.
25. Okamoto I, Kawano Y, Tsuiki H, et al: CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18: 1435-1446, 1999. (Pubitemid 29103631)
26. Okamoto I, Tsuiki H, Kenyon LC, et al: Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160: 441-447, 2002. (Pubitemid 34160321)
27. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: S5054-S5059, 1991.
28. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997. (Pubitemid 27197761)
29. Naor D, Wallach-Dayan SB, Zahalka MA and Sionov RV: Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18: 260-267, 2008.
30. Knudson W: The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci 3: D604-D615, 1998.
31. Harn HJ, Ho LI, Shyu RY, et al: Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22: 107-110, 1996.
32. Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT and Goodwin WJ: Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev 14: 735-739, 2005. (Pubitemid 40489225)
33. De Rossi G, Marroni P, Paganuzzi M, et al: Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 11: 134-141, 1997. (Pubitemid 27065060)
34. Guo YJ, Liu G, Wang X, et al: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422-426, 1994. (Pubitemid 24053180)